EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock

Quick Summary:

WATERTOWN, Mass., Oct.28, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc.(NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock.

The securities will be offered by means of a prospectus supplement and accompanying prospectus relating to the offering that form a part of the registration statement.

EyePoint intends to use the net proceeds that it will receive from the offering to advance clinical development of DURAVYU™ for wet age related macular degeneration (wet AMD) and diabetic macular edema (DME), as well as support its earlier stage pipeline development initiatives, and for general corporate purposes.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Author / Journalist: Globe Newswire

Category: InvestingBusiness

Markets: United StatesChinaHong KongTaiwan

Topics: IPOs News Press Releases EYPT

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-10-28 @ 21:14:19 (2 days ago)

News Timezone: GMT +8:00

News Source URL: benzinga.com

Language: English

Article Length: 1291 words

Reading Time: 8 minutes read

Sentences: 35 lines

Sentence Length: 37 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Benzinga

News ID: 23304868

View Article Analysis

About Benzinga

Main Topics: InvestingBusiness

Official Website: benzinga.com

Update Frequency: 2 posts per day

Year Established: 2010

Headquarters: United States

News Last Updated: 18 hours ago

Coverage Areas: United States

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #54

Publisher Details

Frequently Asked Questions